** Shares of some U.S. drugmakers fall premarket after U.S. President Donald Trump reiterated plans for a "major" tariff on all pharmaceutical imports as his "reciprocal" tariffs took effect
** Trump had also threatened the duties on Friday, after his first set of "reciprocal" tariffs announced last week exempted pharma products
** Shares of Gilead Sciences GILD.O down 2.6%, Eli Lilly LLY.N down 1.5%, Biogen BIIB.O down 1.1% and Pfizer PFE.N down 2.8%
** Amgen AMGN.O shares fall 2.3%, Merck MRK.N down 2%, AbbVie ABBV.N down 2.5%
** The U.S. president has said that the tariffs will incentivize drug companies to move their operations to the U.S.
** Brokerage BMO Capital Markets says the tariffs on pharmaceuticals will "likely do little to shift manufacturing back to the US" as the country already has robust biomanufacturing and fill-and-finish onshore
** Up to last close, LLY down 5.9%, MRK down 20.6%, BIIB down 25.4%, AMGN up 7.5% and GILD up 11.7% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。